A Comparison of Efficacy and Safety of Two Lipid-Based Lubricant Eye Drops for the Management of Evaporative Dry Eye Disease

被引:14
|
作者
Jerkins, Gary [1 ]
Greiner, Jack, V [2 ,3 ]
Tong, Louis [4 ,5 ,6 ]
Tan, Jacqueline [7 ]
Tauber, Joseph [8 ]
Mearza, Ali [9 ,10 ]
Srinivasan, Sruthi [11 ]
机构
[1] Adv Vis Res LLC, Nashville, TN 37205 USA
[2] Clin & & Res Boston, Boston, MA USA
[3] Harvard Med Sch, Dept Ophthalmol, Boston, MA 02115 USA
[4] Natl Univ Singapore, Singapore Natl Eye Ctr, Singapore, Singapore
[5] Singapore Eye Res Inst, Singapore, Singapore
[6] Duke Natl Univ, Singapore Med Sch, Singapore, Singapore
[7] Univ New South Wales, Sydney, NSW, Australia
[8] Tauber Eye Ctr, Kansas City, MO USA
[9] Imperial Coll Healthcare NHS Trust, London, England
[10] Ophthalm Consultants London, London, England
[11] Alcon Res LLC, Johns Creek, GA USA
来源
CLINICAL OPHTHALMOLOGY | 2020年 / 14卷
关键词
dry eye; lipid-deficient; evaporative dry eye; lubricant eye drops; non-inferiority; ARTIFICIAL TEARS; MULTICENTER; DEFICIENT; EMULSION; LAYER;
D O I
10.2147/OPTH.S256351
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: The aim of this study was to compare the efficacy of two lipid-based lubricant eye drops in patients with lipid-deficient dry eye. Methods: This Phase IV, multicenter, prospective, double-masked study enrolled adults (aged >= 18 years) who had a tear film breakup time (TFBUT) of <= 15 seconds(s), and unanesthetized Schirmer I test of >= 3 mm to <= 12 mm in at least one eye, at both screening and baseline visits. Eligible patients (n=231) were randomized (1:1) and received either Systane (R) Balance (SYSB; n=117) or Refresh (R) Optive Advanced (RFO-Ad, n=114), four-times a day, for 35 days. The primary endpoint was non-inferiority for change from baseline in TFBUT at Day 35 (noninferiority was established if the lower limit of the 95% confidence interval (CI) for the difference between the treatment groups was > -1.0 s); secondary endpoints (test of superiority) were change in TFBUTand global ocular discomfort visual analog scale (VAS) score at Day 35. Other endpoints included the impact of dry eye on everyday life (IDEEL) treatment satisfaction scores (inconvenience and effectiveness) and safety. Results: At Day 35, themean change from baseline in TFBUTwas 0.998 s in the SYSB and 0.868 s in the RFO-Ad groups with a treatment difference: 0.130 s; (95% CI -0.34, 0.60; P<0.0001) demonstrating non-inferiority of SYSB to RFO-Ad. The global ocular discomfort VAS scores improved in both groups, with a mean change from baseline of -9.7 and -8.8 in SYSB and RFOAd groups (treatment difference -0.8; P=0.62), respectively. No meaningful difference was observed in IDEEL treatment effectiveness and treatment inconvenience scores between SYSB vs RFO-Ad (P>0.05 for treatment difference). Both treatments were well tolerated. Conclusion: SYSB lubricant eye drops were non-inferior to RFO-Ad for improvement in TFBUT in patients with lipid-deficient dry eye. Both lubricant eye drops improved TFBUT and ocular discomfort scores in patients with lipid-deficient dry eye.
引用
收藏
页码:1665 / 1673
页数:9
相关论文
共 50 条
  • [41] Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
    Burillon, Carole
    Chiambaretta, Frederic
    Pisella, Pierre-Jean
    CLINICAL OPHTHALMOLOGY, 2018, 12 : 2629 - 2636
  • [42] Two-Year Progression of Dry Eye Disease in the Dry Eye Assessment and Management (DREAM) Study
    Lee, Daniel
    Yu, Yinxi
    Bunya, Vatinee
    Asbell, Penny
    Ying, Gui-Shuang
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [43] A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye Disease
    Lambiase, Alessandro
    Sullivan, Benjamin D.
    Schmidt, Tannin A.
    Sullivan, David A.
    Jay, Gregory D.
    Truitt, Edward R., III
    Bruscolini, Alice
    Sacchetti, Marta
    Mantelli, Flavio
    OCULAR SURFACE, 2017, 15 (01): : 77 - 87
  • [44] Assessment of safety, tolerability and efficacy of RP501 eye drops in patients with dry eye disease and subjects wearing contact lenses with lens discomfort
    Garhofer, Gerhard
    Lindner, Theresa
    Pai, Viktoria
    Janku, Patrick
    Bjoerklund, Ulf
    Schmidl, Doreen
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [45] Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-analysis
    Wan, Kelvin H.
    Chen, Li Jia
    Young, Alvin L.
    OCULAR SURFACE, 2015, 13 (03): : 213 - 225
  • [46] Efficacy of Dry Eye Disease Treatment based on the 2007 Report of the International Dry Eye WorkShop (DEWS)
    Utheim, O.
    Raeder, S.
    Utheim, T. P.
    Eidet, J. R.
    Badian, R.
    Stojanovic, A.
    Chen, X.
    ACTA OPHTHALMOLOGICA, 2015, 93
  • [47] Efficacy of Dry Eye Disease Treatment based on the 2007 Report of the International Dry Eye WorkShop (DEWS)
    Utheim, O.
    Raeder, S.
    Utheim, T. P.
    Eidet, J. R.
    Badian, R.
    Stojanovic, A.
    Chen, X.
    ACTA OPHTHALMOLOGICA, 2015, 93
  • [48] Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease
    Yeu, Elizabeth
    Goldberg, Damien F.
    Mah, Francis S.
    Beckman, Kenneth A.
    Luchs, Jodi, I
    Solomon, Jonathan D.
    Whites, Darrell E.
    Gupta, Preeya K.
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 887 - 894
  • [49] Investigation of a novel rabbit nonpolar lipid for the treatment of evaporative dry eye disease in a murine model
    Leonard, Brian
    Hisey, Erin
    Park, Sangwan
    Albert, Daniel M.
    O'Neill, Charles
    Murphy, Christopher J.
    Gadek, Thomas R.
    Li, Jennifer Y.
    Thomasy, Sara M.
    Parikh, Atul N.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [50] Efficacy and Safety of Topical Chloroquine in Mild to Moderate Dry Eye Disease
    Titiyal, Jeewan S.
    Kaur, Manpreet
    Falera, Ruchita
    Bharghava, Ashima
    Sah, Ramkishor
    Sen, Seema
    CURRENT EYE RESEARCH, 2019, 44 (12) : 1306 - 1312